BACKGROUNDER EMBARGOED: WED, NOVEMBER 25, 2015
About Breast Cancer Institute of Australia (BCIA)
The Breast Cancer Institute of Australia (BCIA) is the fundraising and education department of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).
The ANZBCTG is the largest independent, oncology clinical trials research group in Australia and New Zealand. For more than 35 years, the ANZBCTG has conducted a national clinical trials research program for the treatment, prevention and cure of breast cancer. This involves multicentre national and international breast cancer clinical trials and brings together over 700 researchers in 87 hospitals and medical institutions throughout Australia and New Zealand.
Established in 1994, the BCIA aims to raise a sustainable source of funding for the ANZBCTG research program and to increase awareness in the community about the importance of breast cancer clinical trials research.
Profits generated from the sale of For Benefit Medicines’ (FBM) breast cancer medications will be used to identify through clinical trials, new, tailored and effective treatment options for all those diagnosed with breast cancer, and prevention strategies for those at increased risk.
Although the incidence of breast cancer in Australia has continued to rise, there has been a decline in mortality rates associated with the disease1, particularly over the last 20 years. Between 1994 and 2011, there was a 30 per cent drop in the breast cancer mortality rate1 and new treatments now available through breast cancer clinical trials research has played an important part in this improvement.
ROLE OF CLINICAL TRIALS
All of the major milestones in controlling breast cancer worldwide have come through clinical trials, including
Chemotherapy and hormone treatment preventing breast cancer recurrence and saving lives;
Mammograms saving lives through earlier detection;
Removing just the cancer and preserving the breast as a safe and effective treatment for most women;
Preventing breast cancer in some women at increased risk; and
Treatments targeting the specific type of breast cancer can substantially improve outcomes.
All new treatments and procedures must be scientifically proven through clinical trials research before they can be adopted as standard treatment for women diagnosed with breast cancer.
The BCIA conducts a national fundraising program and is fortunate to receive support from many thousands of individuals and community groups, together with a number of well-respected companies. All funds generated support the ANZBCTG research program and are used for the development, implementation, coordination and analysis of new and current clinical trials to:
Identify new, effective and well-tolerated treatments for every person diagnosed with breast cancer;
Identify strategies to improve the quality of life of people affected by breast cancer;
Improve treatment delivery methods; and
Identify new strategies for the prevention of breast cancer.
The BCIA and the ANZBCTG are licensed to fundraise in each State and Territory of Australia.
Kirsten Bruce, 0401 717 566; Ruby Archis, 0413 834 906;
Mark Henderson, 0431 465 004
1. Cancer Australia. Breast Cancer Statistics. Available at: [Last accessed July 2015].
To join the conversation: Like us on Facebook: @For Benefit Medicines
Follow us on Twitter: @FBMAustralia